Biospecimen CRO teams with research center to expand sample access

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Jezperklauzen)
(Image: Getty/Jezperklauzen)
Trans-Hit Bio and Q&T Research have entered into an exclusive strategic partnership, which will provide biopharma customers with access to human biospecimens, for which there is “a great demand,” says exec.

Q&T Research has a multi-therapeutic dedicated research center. It conducts Phase II-III clinical trials and collects human biospecimens in various therapeutic areas.

Trans-Hit Bio is a biospecimen access contract research organization (CRO) with collection capability for biospecimens and clinical samples through a partnered-network of biorepositories.

According to the companies, the partnership will provide biopharma companies with access to blood collected by plasmapheresis from donors and ambulatory patients to be used to prepare large volumes of peripheral blood mononuclear cells (PBMC).

“We receive many requests for human biospecimens every week and we knew there was a great demand for these type of specimens that were not being met, especially for the vaccine R&D field which has needs for blood complement,”​ said Vanessa Tumilasci, PhD, project director, Trans Hit Biomarkers Inc.

Tumilasci told us the partnership is beneficial for both sides: “It brings visibility to Q&T capacity in collecting human biospecimens and for THB it provides its clients with a source for much needed samples.”

THB just started working with Q&T Research, but met the president and general director Pierre Gervais and his team in 2017 – and “the synergism between both companies was evident,”​ Tumilasci said.

“We knew them as a site for clinical trials and the great access to specific populations they have and most recently we learned about their capacity for doing plasmapheresis and isolating PBMCs and blood complement,”​ she added.

Related topics: Preclinical Research

Related news

Show more

Follow us


View more